GlobeNewswire

Northland Power Achieves Major Project Milestone - Hai Long Offshore Wind Project Allocated 300 Megawatts Under Taiwan Feed-in-Tariff Program

Del

TORONTO, April 30, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) today announced that the Taiwan Bureau of Energy ("BOE") has allocated 300 megawatts ("MW") to the Hai Long 2 offshore wind farm ("Hai Long 2") under Taiwan's Feed-in-Tariff ("FIT") program.  This is a significant step forward for the project, as it allocates capacity for Hai Long 2 to connect to Taiwan's grid in 2024, and advances the project's ability to execute a 20-year power contract under Taiwan's FIT regime.  Northland and its partner Yushan Energy Pte. Ltd. ("Yushan Energy") own 60% and 40% of Hai Long 2, respectively. 

Hai Long 2 received its environmental permit in early 2018 and advanced development work is ongoing.  Project economics and financing details will be finalized as development progresses; selection of the turbine supplier and negotiation of construction contracts is underway.

Taiwan has excellent wind resources.  In 2015, the government implemented a FIT program with long-term contracts designed to kick-start its offshore wind sector. Northland has established a meaningful presence in Taiwan, and has been working closely with Yushan Energy to complete all remaining regulatory and permit-related activities needed to execute a power purchase agreement for Hai Long 2 in late 2018. This award also places Northland and its partner, Yushan Energy, in a favourable position to continue to develop their remaining Taiwan opportunities for submission into upcoming procurements.

"Today's announcement reflects Northland's continued growth and leadership in the offshore wind sector," said John Brace, CEO of Northland. "This is a great accomplishment for Northland and its partners. We are proud to support Taiwan in their efforts to create a more sustainable future through the transition to renewable energy."

NORTHLAND POWER'S OFFSHORE WIND STRATEGY

Northland Power's objective is to build a leading global offshore wind ownership and operations platform with a full range of operating, development and investment activities.  Obtaining the FIT allocation for the Hai Long 2 project further contributes to the achievement of this objective.

Taiwan is a key focus for Northland, given its robust economy, good investment climate and strong support for renewable energy.

Hai Long 2 will leverage Northland's European offshore wind development, financing, construction and operations experience and would increase Northland's offshore operating capacity to over 1,450 MW gross capacity (net 1,074 MW to Northland) by 2024.

ABOUT NORTHLAND

Northland is an independent power producer founded in 1987, and publicly traded since 1997. Northland develops, builds, owns and operates facilities that produce 'clean' (natural gas) and 'green' (wind, solar, and hydro) energy, providing sustainable long-term value to shareholders, stakeholders, and host communities.

The Company owns or has a gross economic interest  in 2,458 MW (net 2,029 MW) of operating generating capacity and 252 MW of generating capacity under construction, representing the Deutsche Bucht offshore wind project, in addition to the 300 MW (net 180 MW) just awarded to the Hai Long 2 offshore wind project. Northland's cash flows are diversified over four geographically separate regions and regulatory jurisdictions in Canada and Europe.

Northland's common shares, Series 1, Series 2 and Series 3 preferred shares and Series B and Series C convertible debentures trade on the Toronto Stock Exchange under the symbols NPI, NPI.PR.A, NPI.PR.B, NPI.PR.C, NPI.DB.B, and NPI.DB.C, respectively.

About Yushan Energy Pte Ltd.

Yushan Energy Pte Ltd., is an offshore wind energy business and part of Singapore-based Enterprize Energy Group, a low-carbon energy business, which, in addition to the Hai Long Projects in Taiwan, has operations in Vietnam and the United Kingdom.  The Enterprize Energy Group specializes in the identification and evaluation of early stage development opportunities in Asia and Europe and assembles partnerships to take projects forward through development to financing and construction.

The management team was engaged in the early development of the UK offshore wind sector, notably conceiving and developing the Ormonde Project which achieved several 'global-first' accolades: first commercial project to utilise four-legged 'jacket'-type turbine sub-structures; first commercial deployment of 5MW turbines, and the longest single export cable one-piece installation (42km).

For further information contact:
Barb Bokla, Manager, Investor Relations, (647) 288-1438
Sarah Charuk, Director of Communications, (647) 288-1105

investorrelations@northlandpower.com
www.northlandpower.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Northland Power Inc. via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results18.3.2019 21:45:00 CETPressemelding

On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on Tuesday, March 19 at 10:00 a.m. ET NEW YORK and CLEVELAND, March 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. Interested parties are invited to participate in the call by dialing 844-369-8770 (toll-free domestic) or 862-298-0840 (International) or via webcast at https://www.investornetwork.com/event/presentation/44847. “The diligent work conducted over the past nine months

Novavax Reports Fourth Quarter and Year-End 2018 Financial Results18.3.2019 21:05:00 CETPressemelding

Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018. “In 2018, we committed to focus on our two lead programs, ResVax™ and Nanoflu™, and reflecting on last year’s activities, I am proud to say we have achieved significant results for both,” said Stanley C. Erck, President and CEO of Novavax, Inc. “Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in a Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure. We are now prepared to make meaningful advances on these programs during 2019.” Fourth Quarter 2018 and Subsequent Opera

Mattson Technology Announces Hydrilis™, a Unique High-Productivity Vacuum Wafer Process Platform18.3.2019 17:00:00 CETPressemelding

– Up to 4 process chambers and 8 wafer processing stations – – Smallest footprint, highest throughput platform – – Enables any process chamber, any position configuration flexibility – FREMONT, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Mattson Technology, Inc., a leading supplier of advanced process equipment used to manufacture semiconductors, introduces Hydrilis™, the industry’s highest productivity density vacuum transfer platform featuring high throughput on the smallest footprint. The Hydrilis platform can be configured with up to 4 process chambers, or 8 processing stations, for parallel or sequential wafer processing. Any of the paradigmE® family plasma etch process chambers, Suprema® family plasma photoresist strip and hard-mask removal process chambers, Novyka™ family surface treatment process chambers and Novyka family selective chemical dry etch process chambers can all be integrated on the Hydrilis platform. “Throughput per unit area of fab space is one of the key criteria

Minerva Neurosciences to Host Webcast Event on Schizophrenia18.3.2019 13:30:00 CETPressemelding

Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a webcast, “Schizophrenia: Disease Landscape and Forecast,” on Thursday, March 21, 2019 beginning at 10:00 a.m. eastern time in Boston, MA. Minerva’s Executive Chairman and Chief Executive Officer, Remy Luthringer, Ph.D., will be joined by representatives from Decision Resources Group, a global information and technology services company providing proprietary data and solutions to the healthcare industry, and Dr. Gregory Strauss, an expert key opinion leader. Discussions will feature the following speakers

Infovista Enhances Ipanema SD-WAN with Nextgen Application Intelligence+ and Cloud-Native Orchestration18.3.2019 13:00:00 CETPressemelding

PARIS and ASHBURN, Va., March 18, 2019 (GLOBE NEWSWIRE) -- Infovista, the leader in modern network performance, today announced new cloud-native management and control with next-generation Application Intelligence+ for Ipanema SD-WAN, delivering unmatched application performance across any WAN. Tweet This: Infovista enhances Ipanema SD-WAN with nextgen Application Intelligence+ and cloud native orchestration: https://bit.ly/2ULcKLW #SmarterSDWAN The enterprise network has become the central nervous system of modern digital businesses, and SD-WAN is enabling this digital transformation. Infovista’s Ipanema SD-WAN with new cloud-native management and control of applications tightly combines session-based routing and dynamic path selection of the underlay network with an overlay of deep application visibility and dynamic control of the quality of experience for business-critical applications. Additionally, Ipanema automatically understands application delivery requirements and maintains a

Inspirata and Ohio State University Continue to Break Digital Pathology Barriers18.3.2019 12:30:00 CETPressemelding

Columbus, Ohio Columbus, Ohio, March 18, 2019 (GLOBE NEWSWIRE) -- Less than one year ago Inspirata announced that their digital pathology solution was used to make the first-ever primary digital diagnosis in the U.S., initiating a new era in cancer diagnostics. Today, cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced the company with the help of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC-James) has broken another barrier- Inspirata and the OSUCCC – James have scanned over one-million anatomic pathology slides into high resolution whole slide digital images. “This historic accomplishment has demonstrated that it is possible to create large repositories of diagnostic quality prospective and retrospective slides creating imaging data that will accelerate clinical and research efforts,” says Inspirata Scan Center Manager, Trina Shanks, MLT (ACSP), CPC. Inspirata will presen